Mereo BioPharma Stock Jumps on Alvelestat Licensing Deal with Sentynl

What happened

Mereo BioPharma Group plc (NASDAQ: MREO), a London-based biopharmaceutical company focused on rare diseases, announced on August 11, 2026, that it entered into an Option and License Agreement with Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company.

The agreement gives Sentynl the U.S. commercial and global manufacturing rights to alvelestat, a drug candidate for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Under the deal, Mereo will receive a non-refundable option fee, and if Sentynl exercises the option, Mereo is eligible for $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales.

Mereo will continue to lead the global Phase 3 study and regulatory interactions until the study is completed. During the option period, the companies will collaborate on manufacturing and refine the Phase 3 study design.

Shares of Mereo surged 28.16% on the day, closing at $0.3486, with volume of 136 million shares compared to an average of 3.2 million.

The filing

Mereo filed a Form 8-K with the SEC to report the agreement, as required by Item 1.01 for entry into a material definitive agreement. The company also furnished a press release under Item 7.01 for Regulation FD disclosure, which is attached as Exhibit 99.1.

The 8-K notes that a copy of the agreement is expected to be filed as an exhibit to Mereo's Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

The filing includes standard forward-looking statements, cautioning that clinical development and regulatory processes involve uncertainties.

What this means

A Form 8-K is a 'current report' that public companies must file with the SEC to announce major events that shareholders should know about. Item 1.01 is used when a company enters a material agreement, and Item 7.01 covers voluntary disclosure of information that may be material to investors, such as the press release issued here.

Alvelestat is an investigational drug for AATD-LD, a genetic condition that causes lung damage. The agreement is an option-and-license deal: Sentynl pays a fee to hold the option, and if it exercises it, it gains rights to commercialize alvelestat in the U.S. and manufacture it globally, while Mereo gets substantial payments and royalties.

This is a significant deal for Mereo because it provides potential near-term funding (the option fee) and a pathway to large milestone payments if the drug succeeds. The market's positive reaction reflects investor optimism about the deal's value, though the filing does not explain why the price rose beyond the announcement.

The next steps will hinge on Sentynl's decision to exercise the option, which depends on progress in the Phase 3 study and manufacturing collaboration.